Small Cap Share Ideas: New funding drives Allergy Therapeutics…

A shareholder meeting signed off a A 20million share placing that will allow the company to take its Pollinex Quattro Grass product through to registration in 2019. If the product jumps through the final regulatory hoops then a $2billion a year market beckons.